---
title: "\"DUIBA\" Group's annual loss expands to 109 million RMB"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281290876.md"
description: "DUIBA Group announced its 2025 annual performance, with revenue of 610 million yuan (same below), a year-on-year decrease of 32.7%. The loss expanded from 39.46 million yuan in the same period last year to 109 million yuan; the loss per share is 10.2 cents. No dividend is declared"
datetime: "2026-04-01T02:15:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281290876.md)
  - [en](https://longbridge.com/en/news/281290876.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281290876.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281290876.md) | [English](https://longbridge.com/en/news/281290876.md)


# "DUIBA" Group's annual loss expands to 109 million RMB

DUIBA Group (01753.HK) announced its performance for the fiscal year 2025, with revenue of 610 million yuan (same below), a year-on-year decrease of 32.7%. The loss expanded from 39.46 million yuan in the same period last year to 109 million yuan; the loss per share is 10.2 cents. No dividend is declared

### 相關股票

- [DUIBA (01753.HK)](https://longbridge.com/zh-HK/quote/01753.HK.md)

## 相關資訊與研究

- [DBS downgrades MIXUE Group Class H (2097) to a Hold](https://longbridge.com/zh-HK/news/280429043.md)
- [OSL Group Swings to Loss in 2025](https://longbridge.com/zh-HK/news/281303346.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-HK/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [Mixue Group appoints Zhang Hongfu as co-chairman](https://longbridge.com/zh-HK/news/280280387.md)